NCT03711708已完成4 期
A PHASE IV, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF ZOLOFT (REGISTERED) ORAL SOLUTION (20 MG/ML; FARMASIERRA MANUFACTURING, S.L.) COMPARED TO ZOLOFT (REGISTERED) TABLETS (50 MG; WYETH INDÚSTRIA FARMACÊUTICA LTDA.) IN HEALTHY RESEARCH SUBJECTS UNDER FASTED CONDITIONS
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2018年11月6日最近更新:
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Maximum observed plasma concentration of sertraline (Cmax)
研究概览
简要总结
In Brazil, sertraline is currently available as film coated tablets for oral administration containing sertraline hydrochloride equivalent to 50 mg or 100 mg sertraline.
The sponsor has developed an oral solution formulation containing 20 mg/mL of sertraline, which must be diluted with 120 mL of water, ginger ale, lime/lemon soda or orange juice to be palatable before use. The purpose of this study is to evaluate the relative bioavailability of Zoloft oral solution compared to Zoloft tablets in healthy participants under fasted conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female research subjects and/or male research subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
- •Female research subjects of non-childbearing potential
- •Body mass index (BMI) of 18.5 kg/m2 to 24.9 kg/m2, and a total body weight >50 kg (>110 lbs).
- •Evidence of a personally signed and dated informed consent document indicating that the research subject has been informed of all pertinent aspects of the study.
- •Research subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
- •Clinically significant infections within the past 3 months, evidence of any infection within the past 7 days, history of disseminated herpes simplex infection or recurrent (>1 episode) or disseminated herpes zoster.
- •Evidence or history of cyclic neutropenia.
- •Personal or family history of hereditary immunodeficiency (eg, severe combined immunodeficiency disorder [SCID], Wiskott Aldrich syndrome, X linked agammaglobulinemia).
- •Vaccination with live or attenuated vaccines within 6 weeks prior to dosing, or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks following discontinuation of dosing.
- •Any condition possibly affecting drug absorption (eg, gastrectomy, colon resection, etc.).
- •Research subjects with a history of, or current evidence for, severe gastrointestinal narrowing (pathologic or iatrogenic).
- •History of or current positive results for any of the following serological tests: hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), anti hepatitis C core antibody (HCV Ab), or human immunodeficiency virus (HIV) 1 and
- •A positive urine drug test.
- •A positive alcohol screen.
- •History of regular alcohol consumption exceeding 14 drinks/week for female research subjects or 21 drinks/week for male research subjects [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months before screening.
- •Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. For chewing tobacco, one chew is equivalent to approximately 2 3 cigarettes, so research subjects would be limited to 2 or less chews per day.
- •Treatment with an investigational drug within 6 months or 5 half lives preceding the first dose of investigational product (whichever is longer).
- •Pregnant female research subjects, breastfeeding female research subjects, fertile male research subjects and female research subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol from at least 14 days prior to the first dose of investigational product until at least 28 days after the last dose of investigational product.
- •A positive beta human chorionic gonadotropin test for women of childbearing potential.
- •Use of prescription or nonprescription drugs and dietary supplements within 14 days or 5 half lives (whichever is longer) prior to the first dose of investigational product.
- •Herbal supplements, hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone releasing intrauterine devices [IUDs], vaginal ring, and postcoital contraceptive methods), and hormone replacement therapy must have been discontinued at least 28 days prior to the first dose of investigational product.
- •Depo Provera must have been discontinued at least 6 months prior to the first dose of investigational product.
- •Consumption of grapefruit or grapefruit related citrus fruits (eg, Seville oranges, pomelos) or juices within 7 days prior to dosing.
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 3 months prior to screening.
- •History of sensitivity to heparin or heparin induced thrombocytopenia.
- •History of hypersensitivity to sertraline or any of the components in the formulation of the study products.
- •Unwilling or unable to comply with the criteria in the Lifestyle Requirements section of this protocol.
- •Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the research subject inappropriate for entry into this study.
- •Research subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or research subjects who are the sponsor's employees, including their family members, directly involved in the conduct of the study.
研究组 & 干预措施
Zoloft Oral Solution
Experimental
50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
干预措施: Zoloft Oral Solution (Drug)
Zoloft Tablets
Active Comparator
Zoloft 50 mg tablet.
干预措施: Zoloft tablets (Drug)
结局指标
主要结局
Maximum observed plasma concentration of sertraline (Cmax)
时间窗: Predose (0 h), at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 10, 12, 24, 48, 72, 96, 120, and 144 hours post dose
Area under the sertraline plasma concentration-time curve from time zero to last time point (AUClast)
时间窗: Predose (0 h), at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 10, 12, 24, 48, 72, 96, 120, and 144 hours post dose
次要结局
- Time to first occurrence of Cmax (Tmax) of sertraline(Predose (0 h), at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 10, 12, 24, 48, 72, 96, 120, and 144 hours post dose)
- Sertraline plasma elimination half life (t½)(Predose (0 h), at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 10, 12, 24, 48, 72, 96, 120, and 144 hours post dose)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(Up to 144 hours post dose)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
4 期
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To CymbaltaHealthyNCT03729284Pfizer
已完成
4 期
A Phase IV, single dose JENVAC (Inactivated JE Vaccine) vs. Chinese SA-14-14-2 (Live JE Vaccine) vaccineCTRI/2014/02/004386Bharat Biotech International Ltd
已完成
1 期
A BA/BE study to evaluate the safety, tolerability of endoxifen in healthy human subjectsCTRI/2009/091/000625ambda Therapeutic Research Ltd40
已完成
4 期
A Phase IV, single dose JENVAC (Inactivated JE Vaccine) vs. Chinese SA-14-14-2 (Live JE Vaccine) vaccineCTRI/2016/05/006909Bharat Biotech International Limited
进行中（未招募）
1 期
A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejectioEUCTR2007-001857-24-GBovImmune S.A.12